U. S. Patents (18 filed, 10 issued, see

A few examples: 4,950,770 (1990) – Psoralen Process (licensed to ICN now Valeant); 5,082,964 (1992) -- Cholinesterase Inhibitors;  5,216,176 (1993), 5,356,929 (1994), and 5,473,083 (1995) -- Psoralen Therapeutics (licensed to Baxter Corporation);  Dihydropsoralens & Therapeutic uses,  6,177,424 (2001); Amino- & Mercuriopsoralens 6,255,324 (2001) – under license negotiation. Ten patents granted, eight additional patents pending. 

Examples available for licensing include:

Patent application number - 20120010168

Unique Dual-Action Therapeutics - A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X═C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.

Patent application number - 20110059935

Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS - Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor

Patent application number - 20120059007

Pharmacologically-active vanilloid carbamates - This application relates to pharmacologically-active vanilloid compounds which are useful for the treatment of various anti-inflammatory states characterized by inhibition of FAAH, such as, Alzheimer's dementia, Parkinson's disease, depression, pain, rheumatoid arthritis, pathophysiology of mood disorders, multiple sclerosis, and inflammation, or antagonism of TRPV1, such as, for example, Huntington's disease, hypertension, arthritis, allergic airway inflammation, Crohn's disease, ulcerative colitis, and neuropathic pain.

Patent application number - 20120252891

Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals - Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye.

Patent application number - 20090155224

Dimethyl amino ethyl ether psoralens and methods for their production and use - Water-soluble dimethyl amino ethyl ether psoralens useful in the treatment of proliferative skin disorders, microbial infections and diseases, disorders of the blood and bone marrow of mammals and in microbiocidal compositions for sterilization of blood and blood products and surgical implants and inhibition of microbial growth in industrial applications are provided.